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Abstract
Background: The purpose of the present correlative immunohistochemical study was to assess
the utility of cytokeratin (CK7 and CK20) expression in the diagnosis of short-segment Barrett
esophagus, particularly its efficacy in differentiating Barrett mucosa from intestinal metaplasia of the
gastric cardia and corpus.
Methods: Two groups of endoscopic biopsy specimens were examined, including 20 endoscopic
biopsy specimens of short-segment Barrett esophagus (Group A) and equal number exhibiting
Helicobacter pylori associated intestinal metaplasia of the gastric cardia and corpus (Group B). All
were investigated by immunohistochemistry using the standard ABC method for CK7 and CK20
expression. Fisher's exact test was used for statistical analysis of Barrett CK7/20 and gastric CK7/
20 patterns between the groups.
Results: The anticipated pattern of reactivity in Barrett mucosa (CK7: strong diffuse positivity in
superficial and deep glands; CK20: positivity in surface epithelium and superficial glands) was seen
in 2 cases of Group A specimens. The expected gastric pattern (CK7: patchy immunostaining with
variable involvement of deep glands; CK20: patchy immunostaining of superficial and deep glands in
incomplete intestinal metaplasia / absence of CK7 immunoreactivity with strong CK20 staining in
superficial and deep glands in complete intestinal metaplasia) was seen in 8 cases of Group B
specimens. The respective sensitivity and false-negativity values of CK7/20 staining for Barrett
pattern in Group A were 10% and 90%, respectively. These values for gastric pattern in Group B
were 40% and 60%, respectively. The specificity and false-positivity values of both patterns were
same (100% and 0%, respectively). There was no statistically significant difference for Barrett
pattern between the two groups (P  = 0.487), while the observation of gastric pattern was
significantly higher in Group B than in Group A (P = 0.02).
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Conclusions: We concluded that these hypothesized and recently applied diagnostic criteria
involving CK7 and CK20 immunoreactivity are not reliable in distinguishing short-segment Barrett
esophagus from intestinal metaplasia as seen in gastric cardia and corpus.
Background
Barrett esophagus (BE) is associated with an increased risk
of esophageal adenocarcinoma, a malignancy that has
had a rapid rising incidence recently [1-3]. The etiology of
BE is unknown, but genetic predisposition with ulcerative
changes from gastro-esophageal reflux disease (GERD)
might be responsible [4].
BE should be suspected at the endoscopy when the nor-
mal, whitish-appearing squamous epithelium is replaced
by a red, velvety-appearing mucosa in the distal esopha-
gus. The reliable diagnosis of BE is difficult related to sam-
pling errors due to determination of the exact location of
the gastro-esophageal junction such as in hiatal hernia.
Diagnostic difficulties arise when the endoscopist deals
with the short-segment BE. Junctional, fundic and special-
ized (intestinal) types of glandular epithelium were
described for the definition of BE by Paull et al. [5]. But it
was recently reported that the detection of the latter is a
reliable criterion for the diagnosis of BE [4,6]. Helicobacter
pylori  (H. pylori) might be associated with carditis and
intestinal metaplasia of the cardia [7]. Therefore, intesti-
nal metaplasia involving the cardia related to Helicobacter
gastritis can be histologically indistinguishable from
intestinal metaplasia of the distal esophagus.
It has been suggested that cytokeratin subsets 7 and 20
(CK7 and CK20) might be useful to distinguish both long-
and short-segment of BE from intestinal metaplasia of the
proximal stomach [8-11]. The purpose of this study was to
evaluate the cytokeratin (CK7 and CK20) expression in
the diagnosis of short-segment Barrett esophagus, particu-
larly its utility in differential diagnosis of Barrett mucosa
from intestinal metaplasia of the gastric cardia and
corpus.
Methods
Endoscopy specimens of the patients referred from Mar-
mara University Institute of Gastroenterology were
reviewed from the files of the Department of Pathology at
the same university between 1998 and 2002. At least 4
biopsies were taken from irregular squamo-columnar
junction (SCJ) with peninsulas or tongues of columnar
epithelium and islands of squamous or columnar epithe-
lium for each case. When more than one peninsula or
tongue of columnar epithelium in the distal esophagus
was observed endoscopically, 4 biopsies was taken from
each peninsula and they were sent to histopathologic
examination in separate eppendorph tubes. Small penin-
sulas with linear vessels distal to the SCJ and any focal
abnormality were also biopsied.
Esophageal and gastric biopsies were taken antegrade or
retrograde with retroflexion of the endoscope when it was
necessary. The retroflexed approach was preferred for
sampling of cardia. The cases which were diagnosed his-
topathologically as short-segment BE were included to the
study. Short-segment BE was defined endoscopically as
tongues less than 3 cm in length above the esophago-gas-
tric junction (EGJ) with its resemblance to small intestine
having well-formed microvilli and intestinal metaplasia
either with hematoxylin and eosin (H&E) (Figure 1) or
Alcian blue pH2.5 positive goblet cells (Figure 2) on
microscopic examination.
The study group consisted of 20 patients with short-seg-
ment BE (Group A) and the equal number of patients with
gastric intestinal metaplasia (cardia and corpus) accompa-
nied by H. pylori gastritis (Group B). Biopsy specimens
that were obtained within 5 mm distance below the EGJ
were considered as cardiac mucosa.
Specimens were fixed in 10% buffered formalin and
embedded in paraffin. Serial sections were cut from each
specimen. All sections were stained with routine H&E
stain. Periodic acid Schiff (PAS), Alcian blue pH 2.5 and
Alcian blue pH 0.5 were used to identify neutral mucin,
sialomucin and sulphomucin, respectively. Giemsa stain
was used to reveal H. pylori. We excluded the cases without
detected goblet cell metaplasia by Alcian blue stain for
both Group A and Group B. H. pylori infection was con-
firmed with Giemsa stain for the cases in Group B.
Endoscopic biopsies were grouped as complete (type I) or
incomplete (type II) intestinal metaplasia according to the
previously defined criteria [12]. The proposed Barrett
CK7/CK20 pattern (CK7: strong diffuse positivity in
superficial and deep glands; CK20: positivity in surface
epithelium and superficial glands) and gastric CK7/CK20
pattern (CK7: patchy immunostaining with variable
involvement of deep glands; CK20: patchy immunostain-
ing of superficial and deep glands in incomplete intestinal
metaplasia / absence of CK7 immunoreactivity with
strong CK20 staining in superficial and deep glands in
complete intestinal metaplasia) were evaluated for all
cases. Six control biopsies were constituted retrospectively
from patients whose biopsies showed normal SCJ (n = 3)
and normal cardia (n = 3) microscopically.BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/5
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Group A
Clinical data including age, sex, gastro-esophageal reflux
symptoms, and endoscopic findings and short-segment
Barrett mucosa were obtained from each case. The
patients with BE within the last 3 cm of distal esophagus
were included to the Group A. Patients with positive H.
pylori were excluded from the study.
Group B
Clinical data including age, sex, gastro-esophageal reflux
symptoms, endoscopic findings, and H. pylori status were
obtained from each case. Patients with positive H. pylori
were included to the study. Twenty endoscopic biopsies
(cardia, n = 9 and corpus, n = 11) with histologic evidence
of intestinal metaplasia were studied.
Immunohistochemical studies
One tissue block was selected for each case. The blocks
were cut at 5 µm sections. Slides were deparaffinized and
rehydrated through graded alcohols. Antigen retrieval was
performed by using citrate buffer in microwave both for
CK7 and CK20. Slides were incubated in 3% hydrogen
peroxide/methanol for 20 min to block nonspecific back-
ground staining due to endogenous peroxidase. Using the
standard streptavidin-biotin peroxidase complex (ABC)
method, CK7 (clone OV-TL 12/30, Neomarkers, Fremont,
CA, USA) and CK20 (clone K20.4, Neomarkers, Fremont,
CA, USA) were performed on all slides. The slides were
incubated for 30 minutes in secondary antibody solution.
Diaminobenzidine (DAB) served as the chromagen. The
slides were counterstained with hematoxylin. The samples
of breast carcinoma and colon carcinoma were used as
positive controls for CK7 and CK20, respectively. Negative
controls were produced with the same tumor samples and
staining methods by omitting the primary antibodies.
Statistical Analysis
Fisher's exact test was used for analysis of Barrett and gas-
tric patterns. A result was considered statistically signifi-
cant if the P value was less than or equal to an alpha-level
of 0.05.
Section from gastro-esophageal junction showing BE with goblet cells, H&E, ×40 Figure 1
Section from gastro-esophageal junction showing BE with goblet cells, H&E, ×40BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/5
Page 4 of 8
(page number not for citation purposes)
Results
In total, 40 patients were included to the study. The
median age of the patients was 46 (range, 28–77) years in
Group A and 50 (range, 25–73) years in Group B. The
male to female ratio was 4 to 1 in Group A, whereas it was
2 to 3 in Group B. The clinical and immunohistochemical
features were summarized in Table 1.
Group A
Reflux symptoms were found in 14 cases (70%) with BE.
High frequency of hiatal hernia (65%) was found in this
group. Three cases showed low-grade dysplasia out of
total. Thirteen cases revealed incomplete intestinal meta-
plasia and 7 cases were complete intestinal metaplasia by
using Alcian blue stain. The anticipated Barrett CK7/20
pattern was identified only 2 of the 20 cases (Figure 3).
Intense blue staining of goblet cells with Alcian blue pH 2.5/PAS, ×40 Figure 2
Intense blue staining of goblet cells with Alcian blue pH 2.5/PAS, ×40
Table 1: Clinical and immunohistochemical findings in patients with short-segment BE and gastric intestinal metaplasia
Short-segment BE (n = 20) Gastric intestinal metaplasia (n = 20)
Age (yr)a 28–77 25–73
Male/Female 4/1 2/3
Barrett CK7/20 patternb (%) 10 0
Gastric CK7/20 patternc (%) 5 40
Other patterns (%) 85 60
a Range b Defined in reference #8 c Defined in reference #8BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/5
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One case showed anticipated gastric CK7/CK20 pattern.
The reminder had variable staining patterns; like no
immunostaining (n = 6) or focal immunostaining (n =
11) for CK7 with focal or diffuse immunostaining for
CK20, which did not fit in with the anticipated Barrett
CK7/20 pattern (Figure 4). The sensitivity, specificity,
false-positivity, and false-negativity of CK7/20 staining for
Barrett pattern were 10%, 100%, 0%, and 90%,
respectively.
a. Diffuse moderate CK7 immunostaining of superficial and deep glands in BE, ×40 Figure 3
a. Diffuse moderate CK7 immunostaining of superficial and deep glands in BE, ×40, b. Band-like CK20 immunostaining of sur-
face epithelium and superficial glands in BE, ×40
a. Absent CK7 immunostaining in BE, ×100, b. Patchy CK20 immunostaining of superficial and deep glands in BE, ×100 Figure 4
a. Absent CK7 immunostaining in BE, ×100, b. Patchy CK20 immunostaining of superficial and deep glands in BE, ×100BMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/5
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Group B
Eleven cases showed complete intestinal metaplasia,
whereas 9 cases showed incomplete intestinal metaplasia
by using Alcian blue stain. Eight cases expressed the gastric
CK7/20 pattern (cardia, n = 5 and corpus, n = 3). Six of
them showed complete and 2 incomplete gastric CK7/20
pattern. Barrett CK7/20 pattern was not observed in any
patient with gastric intestinal metaplasia. The staining
characteristics of the remaining 12 cases did not fit in with
the anticipated gastric CK7/20 pattern; due to the patchy
CK7 and/or focal CK20 immunopositivity in cases with
complete intestinal metaplasia and absence of CK7
immunopositivity and/or diffuse CK20 immunopositivity
in cases with incomplete intestinal metaplasia. The sensi-
tivity, specificity, false-positivity, and false-negativity of
CK7/20 staining for Barrett pattern were 40%, 100%, 0%,
and 60%, respectively.
There was no significant difference for Barrett pattern
between the two groups (2/20 in Group A vs. 0/20 in
Group B, P = 0.487), while the observation of gastric pat-
tern was significantly higher in Group B than in Group A
(8/20 vs. 1/20, P = 0.02).
Normal SCJ showed patchy immunopositivity for CK7
without any immunoreactivity for CK20, but normal gas-
tric cardia revealed immunonegativity for CK7 combined
with patchy immunopositivity for CK20, which is limited
to the surface epithelium.
Discussion
Intestinal metaplasia may develop in the cardia in
patients either with short-segment BE or carditis especially
caused by H. pylori. Distinction between these two entities
is important since the etiology and risk of developing ade-
nocarcinoma are different [7]. BE is believed to be caused
by GERD and associated with an increased risk of esopha-
geal adenocarcinoma [1,2,4]. Microscopically, BE can be
defined as replacement of the esophageal squamous epi-
thelium by metaplastic specialized (intestinalized)
columnar epithelium. Other epithelial types are junc-
tional type and fundal type of epithelia. The diagnosis of
BE requires biopsy confirmation of intestinal metaplasia
with Alcian blue pH2.5 positive goblet cells in addition to
typical endoscopic findings. The exact level of SCJ, proxi-
mal aspect of the gastric folds, and linearly oriented
mucosal vessels in the distal esophagus and EGJ should be
identified [13]. SCJ normally corresponds to the proximal
margin of the linear gastric folds which means EGJ. The
small vessels oriented parallel to the long axis of the
esophagus disappear at the normally located SCJ. How-
ever, detection of abnormal extension of these vessels
below the SCJ and above the proximal margin of gastric
folds is an evidence of the presence of columnar epithe-
lium in the distal esophagus [14].
Distinguishing BE from other entities which may render
similar histopathologic features is paramount. Because of
no absolute histological criteria for diagnosing Barrett
mucosa has been established yet, recent studies [8-11,15-
19] mainly depend on patterns of some cytokeratin sub-
sets, especially two distinct patterns of CK7/20 staining.
Cytokeratins are highly conserved polypeptides and repre-
sent a group of cytoskeletal structural proteins present in
all epithelia. There are at least 20 distinct forms of cytok-
eratins in epithelial cells and variable patterns of expres-
sion depending on the type, location, and differentiation
of the epithelium [20]. CK7, essentially, is not expressed
in normal epithelium of the gastrointestinal tract, whereas
CK20 is expressed in intestinal epithelium, gastric foveo-
lar epithelium, and endocrine cells in the upper portions
of the pyloric glands. Barrett CK7/20 pattern was first
defined by Ormsby et al. [8] as staining of the superficial
epithelium for CK20 and staining of both superficial and
deep metaplastic epithelium for CK7. The designated gas-
tric CK7/20 pattern was grouped into two patterns regard-
ing the type of the intestinal metaplasia (incomplete/
complete) by the same authors. According to their sugges-
tion, patchy CK7 expression with variable involvement of
deep glands was seen in incomplete gastric intestinal
metaplasia, whereas strong CK20 expression in superficial
and deep glands with the absence of CK7 expression was
seen in complete gastric intestinal metaplasia. In this pio-
neering study, Barrett CK7/20 pattern was highly sensitive
and specific when compared to cases with gastric intesti-
nal metaplasia. However, H. pylori status of the cases was
not mentioned. Studies by Glickman et al [9] and
Jovanovic et al. [15] confirmed Ormsby's findings in 91%
and 94% of their cases with long-segment BE, respectively.
On the other hand, studies by some other researchers have
not been able to support Ormsby's findings; the proposed
Barrett CK7/20 pattern was found in 54% of patients with
long-segment BE by Mohammed et al. [16] and only 39%
of patients with long-segment BE by El-Zimaity et al. [17].
Ormsby et al. [11] later assessed the utility of CK7/20 pat-
terns in short-segment BE in another study and found that
"diagnostic" Barrett CK7/20 pattern was present in 82% of
patients with short-segment BE. Although Mohammed et
al. [16] found almost the same percentage (81%) for the
short-segment BE cases with Ormsby et al. [11], they
found the same pattern in 30.7% of patients with intesti-
nal metaplasia in cardia and more interestingly in 55% of
biopsies which had either normal or inflamed gastric
mucosa without intestinal metaplasia.
In the present study, 10% of patients with short-segment
BE showed the anticipated CK7/20 pattern and 40% of
patients with gastric intestinal metaplasia showed the
anticipated gastric CK7/20 pattern with appropriate com-
plete or incomplete intestinal metaplasia. The sensitivityBMC Clinical Pathology 2003, 3 http://www.biomedcentral.com/1472-6890/3/5
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of Barrett CK7/20 pattern was very low (10%) in the BE
group despite its high specificity (100%). The sensitivity
of gastric CK7/20 pattern was also low (40%) in gastric
intestinal metaplasia group, although the specificity was
high (100%) in this group as well. Gastric CK7/20 pattern
was significantly higher in gastric intestinal metaplasia
group than in BE group (P = 0.02), whereas Barrett CK7/
20 pattern did not significantly differ between the two
groups (P = 0.487). Based on these results, to use two dis-
tinct patterns of CK7/20 staining could not be accepted as
a reliable method in differentiating short-segment BE
from gastric intestinal metaplasia since both patterns have
very low sensitivity and very high false-negativity values.
In the Couvelard's study [10] 31% of patients and in the
Ormsby's study 15% of patients with short-segment BE
associated with Barrett CK7/20 pattern had H. pylori infec-
tion. Although the percentage of the positive H. pylori
cases in patients with short-segment BE associated with a
Barrett CK7/20 pattern was not mentioned in the Moham-
med's study [16], 6% of patients had H. pylori infection
with short-segment BE. Since intestinal metaplasia may be
seen both in H. pylori infection and BE, combination of
these entities should not be of the interpreted for evaluat-
ing the utility of the cytokeratin subsets. We excluded the
H. pylori positive cases even if it was diagnosed as BE.
Therefore, the differences between our study and previ-
ously reported results may have been due to this strict dis-
tinction of H. pylori positive BE cases in the present study.
Differences in biopsy protocols between previous studies
and the present study (number, size or site of the speci-
men, anterograd or retroflexed approach) might have
been another reason for differences in the results. To iden-
tify the exact location of the cardia anterograd approach
should be used. However, regarding the normal cardiac
epithelium, its existence remains still unclear, since the
results of different studies are contradictory [21-23].
While the two studies suggest that normal cardiac epithe-
lium represents a form of metaplastic epithelium second-
ary to gastro-esophageal reflux [21,22], another study
reported by Kilgore et al suggests that cardiac mucosa
exists as a native structure [23]. Further studies may pro-
vide information on the cardiac mucosa, especially its'
relation with reflux changes and BE.
Conclusions
On the basis of our results, we are less confident of the use
of the proposed CK7/20 patterns for differentiating short-
segment BE from gastric intestinal metaplasia. It is impor-
tant to recognize the endoscopic features that aid the diag-
nosis of BE for endoscopists, since the histology of
intestinal metaplasia in cardia related to other etiologies
and Barrett esophagus is identical. We suggest that the def-
inition of BE should be based on the clinic, endoscopic,
and histological findings rather than the pattern of CK7/
20 immunostaining.
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